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The ACE trial: A randomized comparison of open
versus endovascular repair in good risk patients
with abdominal aortic aneurysm
Jean-Pierre Becquemin, MD, Creteil, France
Endovascular repair of infrarenal abdominal aneurysms (EVAR) is currently used in patients with large aneurysm. Two
randomized studies, Dutch Randomised Endovascular Aneurysm Management (DREAM) and Comparison of Endovas-
cular Aneurysm Repair with Open Repair in Patients with Abdominal Aortic Aneurysm (EVAR-1), showed favorable
early results with EVAR; but at 2 and 4 years, the rates of all-cause mortalities were no longer different. Patients in EVAR
groups required more reinterventions. These data were confirmed by national audits and large registries. However, there
is still uncertainty concerning the durability of the devices, and long-term results are unknown. The ACE (Anevrysme de
l’aorte abdominale, Chirurgie versus Endoprothese) trial is a multicenter, prospective randomized trial aimed at assessing
the results of EVAR and of open surgery in relatively good-risk patients presenting with an asymptomatic abdominal
aortic or aortoiliac aneurysm. The primary end point is death and major complications up to 5 years after randomization.
Analysis of results is underway, and publication due by the end of the year. ( J Vasc Surg 2009;50:222-4.)Abdominal aortic aneurysm (AAA) rupture is a major
cause of cardiovascular death in industrialized countries.
Prophylactic repair is advised for large aneurysms in good-
to moderate-risk patients. Although endovascular AAA re-
pair (EVAR) is an attractive option because of its less
invasive nature, there is still a room for uncertainty con-
cerning its durability and overall long-term efficacy com-
pared with open repair.
Two large randomized controlled trials, Comparison of
Endovascular Aneurysm Repair with Open Repair in Pa-
tients with Abdominal Aortic Aneurysm (EVAR-1) and
Dutch Randomised Endovascular Aneurysm Management
(DREAM),1,2 showed similar results. The EVAR-1 trial
enrolled 1082 patients with a 30-daymortality of 1.7% after
EVAR and 4.7% after open repair; the DREAM trial re-
ported 1.2% mortality after EVAR and 4.6% after open
repair. At 2 years for DREAM,3,4 and 4 years for EVAR-1,
the all-cause mortality was not different in the two arms.
The aneurysm-related mortality was lower in the EVAR
groups, but the rate of reinterventions was significantly
higher.
National institutes around the world issued various
recommendations. In the United Kingdom, the National
Institute for Health and Clinical Excellence (NICE) Com-
mittee concluded that endovascular stent grafts were an
appropriate use of National Health Service resources. In
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222other countries such as Canada, Belgium, and France,
however, health care resource providers were more conser-
vative and asked for more data and longer follow-up. In
France, although the regulation may change soon, reim-
bursement is still limited to high-risk patients as defined
by the Agence Française de Securité Sanitaire (AFSSAPS;
Table I).
The main question remains the long-term durability of
EVAR. Rupture after EVAR occurs, and it is still uncertain
whether the early benefit of EVAR will not be reversed by
better long-term results with open repair. Of concern is
that the DREAM principal investigator stated in an oral
presentation in November 2008 (personal communication,
J. D. Blankensteijn, 2008) that EVAR may be associated
Table I. Current criteria for endovascular treatment of
abdominal aortic aneurysm by stent graft legislation
issued by the Agence Française de Securité Sanitaire
(AFSSAPS) in 2003 and still valid in 2009
AFSSAPS criteria
● Abdominal aortic aneurysm 50 mm or growth 1 cm in 1
year
● Age 80 years old
● Coronaropathy defined by a past history of myocardial infarc-
tion, angina pectoris, positive functional tests, and coronary
intervention (percutaneous transluminal angioplasty or coro-
nary artery bypass grafting) not feasible or not indicated
● Cardiac insufficiency with clinical symptoms
● Noncorrectable tight aortic valve stenosis
● Left ventricular ejection fraction 40%
● Respiratory insufficiency defined by
Forced expiratory ventilation in 1 second 1.2/s
Vital capacity 50% of the predicted value
PaCO2 45 mm Hg or PaO2 60 mm Hg
Permanent oxygen therapy
● Serum creatinine 200 mol
● Hostile abdomenwith a higher mortality rate than open repair at 5 years. On
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improved reliability of the most recent devices.
The ACE (Anevrysme de l’aorte abdominale, Chirurgie
versus Endoprothèse) trial was conceived in 1998 when no
level 1 evidence existed. ACE is a multicenter, prospective
randomized trial to assess the results of EVAR and of open
surgery in relatively healthy patients presenting with an
asymptomatic abdominal aortic or aortoiliac aneurysm.
PROTOCOL
Inclusion criteria. Inclusion criteria combined anat-
omy and physical status assessment:
● Anatomic assessment was based on computed tomogra-
phy (CT) scan evaluation. Patients were eligible when
the AAA was 50 mm in men or 45 mm in women.
The upper neck, calculated from the lower renal artery to
the aneurysm sac, had to measure at least 15 mm in
length and be free of major thrombus or of circular
calcification. The angle between the axis of the aneurysm
and the axis of the neck could not exceed 60°. The iliac
arteries had to be large enough to be compatible with the
introducer sheath. Bifurcated as well as aortouniiliac
grafts could be used.
● Physical status assessment included age, cardiac, renal,
and pulmonary evaluation according to the criteria of the
Society for Vascular Surgery/American Association for
Vascular Surgery comorbidity score.
Randomization. Data were collected by fax from the
various centers at the Clinical Research Unit (URC) of
Henri Mondor Hospital. After randomization by the cen-
ter, arm allocation was notified 24 hours.
Follow-up. Patients were seen at 1, 6, and 12months,
and yearly thereafter for the duration of the study (mini-
mum 1 year for each patient). In the EVAR arm, a contrast
CT scan was performed at each interval, whereas in the
open repair, group the scan was performed at the end of
follow-up. Plain radiographs and duplex scans were also
performed at each interval in the EVAR group. All events
and surveillance data, including eventual rehospitalizations,
were collected in the case report form.
End points. The primary end point was death of any
cause and major adverse events, defined as myocardial
infarction, permanent stroke, permanent hemodialysis, ma-
jor (leg or thigh) amputation, paraplegia, bowel infarction,
and reinterventions for graft replacement. Secondary end
points included minor complications.
Statistical analysis. Statistical analysis will compare by
log-rank test the actuarial survival and the freedom from
major adverse events for the duration of the study in the
two arms. Cox logistic regression analysis will evaluate the
influence of prognosis parameters such as anatomic factors
and risk factors.
Study organization and surveillance. Five commit-
tees were set up to organize and monitor the on-going
study: a steering committee, a scientific committee, a com-
mittee for center selection, a committee for end points andadverse events validation, and a committee for safety issue.
Each committee meets at regular intervals.
All data are monitored by comparing case report forms
and data trial sheets to check for accuracy. End points are
validated by a specific independent committee that consists
of anesthesiologists, cardiologists, vascular surgeons, radi-
ologists, and internists.
TRIAL UPDATE
The ACE protocol was approved by the Henri Mon-
dor Hospital ethical committee in 1998 and is identified
at the ClinicalTrials.gov identifier under the number
NTC00224718. A grant of €600,000 was obtained from the
Programe Hospitalier de Recherche Clinique (PHRC) of the
Ministry of Health (MOH) in 1999, and was transferred to
the Clinical Research Center for Délégation à la Recherche
Clinique (DRC), which is in charge of the committee for end
points and adverse events validation, the safety committee, the
organization, and the data monitoring and analysis.
The grant alone could not cover the cost of the stent
grafts and, since then, no reimbursement of the graft by
Caisse Nationale d’Assurance Maladie (CNAM) [Social
Security] has been available because the CNAM advocated
that its role was not to fund research. The following solu-
tions were found: in the public sector, grafts were pur-
chased by the hospitals from their own budget, and firms
provided a limited number of free grafts to the private
sector.
Regulations were changed at the date the trial was
expected to begin: the organization of the Agence Natio-
nale d’Evaluation Médicale changed to become Agence
Française de Sécurité Sanitaire Pour la Santé (the National
Health Agency), and for1 year, the use of any stent graft
was forbidden until each device was assessed and approved
by a specific committee. Then, insurance issues and agree-
ments between administration of the various centers and
the DRC added more delay. Finally, the very first patient
was enrolled in 2003. Between 2003 and 2008, 25 vascular
centers from university and private hospitals in France
contributed to the study.
Randomization was slow for a variety of reasons: First,
funding was lacking for the stent grafts.
Second, strict regulatory limitation of EVAR to high-
risk patients by AFSSAPS, in which violating these limita-
tions could mean fines and being forbidden to practice for
1 to several months. Although surgeons were covered
within the framework of the study, many became reluctant
to randomize good-risk patients.
Third, publication of the early results of DREAM and
EVAR-1 trials in 2004 reduced the enthusiasm of some
participating centers.
Given this evolution, the scientific committee decided
to stop the enrollment by March 2008 and to extend the
follow-up for 3 more years. So far, a cohort of 306 patients
is being followed up, and data from 1 to 5 years are
available. Most of collected data are now stored in a data-
base and double-checking of the accuracy of the stored
items is currently ongoing. The committee of end point
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collected with a strict control of the concordance with
patient’s records. Interim analysis is due September 2009,
with the initial publication by the end of 2009.
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Several multicenter randomized trials have compared endo-
vascular and open repair options in good-risk aneurysm pa-
tients, including the Comparison of Endovascular Aneurysm
Repair with Open Repair in Patients with Abdominal Aortic
Aneurysm (EVAR-1) and Dutch Randomised Endovascular
Aneurysm Management (DREAM) European studies that re-
ported an early survival advantage after endovascular repair. The
Veterans Affairs Study in the United States (OVER) completed
recruitment of 881 patients in April 2007 and results are
expected soon.
The Anévrisme de l’aorte abdominale: Chirurgie versus Endo-
prothèse (ACE) study from France uses a similar study protocolscribes the challenges the French investigators have faced with
regulatory bodies and funding agencies resulting in patient recruit-
ment lagging 5 years after initial ethics approval. This environment
may have contributed to the emergence of laparoscopic aortic
surgery as a minimally invasive therapeutic option, which French
surgeons have been pivotal in developing.
The ACE investigators should be commended for their perse-
verance in completing this study. One wonders, though, with 306
patients recruited whether we will see a repeat of the early DREAM
results (345 patients), where the early survival advantage was
similar to that achieved with EVAR-1 and was viewed as clinically
significant, but failed to reach statistical significance. Regardless,
we await the results, which should be interesting and valuable.
